Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Double-blind phase: The objective of the study was to evaluate the efficacy and safety of
Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of perennial allergic
rhinitis.
Open-label Phase: The objective of this extension was to evaluate the long-term safety of
Bilastine 20 mg during one year in the symptomatic treatment of perennial allergic rhinitis